Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation (CBYL719G12301)

  • Details

ClinicalTrials.gov ID: NCT04208178
Diagnosis Type: Breast Cancer
USOR Number: 19113

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation (CBYL719G12301)

  • Details

ClinicalTrials.gov ID: NCT04208178
Diagnosis Type: Breast Cancer
USOR Number: 19113

  • Practice Details

4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2000

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Aurora

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation (CBYL719G12301)

  • Details

ClinicalTrials.gov ID: NCT04208178
Diagnosis Type: Breast Cancer
USOR Number: 19113

  • Practice Details

1700 S Potomac Street
Aurora, CO 80012
P: (303) 418-7600

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Littleton

EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation (CBYL719G12301)

  • Details

ClinicalTrials.gov ID: NCT04208178
Diagnosis Type: Breast Cancer
USOR Number: 19113

  • Practice Details

22 W Dry Creek Circle
Littleton, CO 80120
P: (303) 730-4700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lone Tree

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: Breast Cancer
USOR Number: 21205

  • Practice Details

10107 RidgeGate Parkway, Suite 200
Lone Tree, CO 80124
P: (303) 925-0700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lakewood

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: Breast Cancer
USOR Number: 21205

  • Practice Details

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: Breast Cancer
USOR Number: 21205

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: Breast Cancer
USOR Number: 21205

  • Practice Details

4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2000

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Aurora

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: Breast Cancer
USOR Number: 21205

  • Practice Details

1700 S Potomac Street
Aurora, CO 80012
P: (303) 418-7600

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Thornton

A Phase 3, double-blind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

  • Details

ClinicalTrials.gov ID: NCT04964934
Diagnosis Type: Breast Cancer
USOR Number: 21173

  • Practice Details

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

More Details View Practice Page
1 2 3 77